MRX-2843 is primarily investigated for its potential in cancer therapy, particularly targeting resistant forms of cancer. It functions as a dual inhibitor of Mer and Axl receptor tyrosine kinases, which are often implicated in tumor growth, metastasis, and resistance to conventional treatments. By blocking these pathways, MRX-2843 aims to reduce tumor proliferation and enhance the effectiveness of other cancer therapies. Its application is especially relevant in cases where cancers develop resistance to standard treatments, offering a promising approach to overcoming therapeutic challenges. Research is ongoing to explore its efficacy and safety in clinical settings.